Johnson & Johnson vs Pfizer Inc.
In their latest fiscal years, Johnson & Johnson reported revenue of $94.19B and Pfizer Inc. reported $62.58B — JNJ was 1.5× larger by revenue. Net income was $26.80B for JNJ and $7.77B for PFE.
| Latest fiscal year | JNJ · FY ended Dec 2025 | PFE · FY ended Dec 2025 |
|---|---|---|
| Revenue | $94.19B | $62.58B |
| Revenue growth | +6.0% | −1.6% |
| Net income | $26.80B | $7.77B |
| Net margin | 28.5% | 12.4% |
| Diluted EPS | $11.03 | $1.36 |
| Operating cash flow | $24.53B | $11.70B |
| Total assets | $199.21B | $208.16B |
| Total liabilities | $117.67B | $121.39B |
| Shareholders' equity | $81.54B | $86.48B |
| Cash & equivalents | $19.71B | $1.14B |
Revenue over time
Go deeper
Both columns use the same XBRL concepts where possible, but companies may define revenue and other line items differently. Banks, insurers and industrial companies are not directly comparable on margins. Source: SEC EDGAR XBRL company facts. Not investment advice.